首页> 外文期刊>Immunity >The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.
【24h】

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.

机译:端粒酶催化亚基是被细胞毒性T淋巴细胞识别的广泛表达的肿瘤相关抗原。

获取原文
获取原文并翻译 | 示例
           

摘要

The discovery of tumor-associated antigens (TAA) in certain human malignancies has prompted renewed efforts to develop antigen-specific immunotherapy of cancer. However, most TAA described thus far are expressed in one or a few tumor types, and, among patients with these types of tumors, TAA expression is not universal. Here, we characterize the telomerase catalytic subunit (hTERT) as a widely expressed TAA capable of triggering antitumor cytotoxic T lymphocyte (CTL) responses. More than 85% of human cancers exhibit strong telomerase activity, but normal adult tissues, with few exceptions, do not. In a human system, CD8+ CTL specific for an hTERT peptide and restricted to MHC HLA-A2 lysed hTERT+ tumors from multiple histologies. These findings identify hTERT as a potentially important and widely applicable target for anticancer immunotherapeutic strategies.
机译:在某些人类恶性肿瘤中肿瘤相关抗原(TAA)的发现促使人们重新致力于开发针对癌症的抗原特异性免疫疗法。然而,迄今为止描述的大多数TAA在一种或几种肿瘤类型中表达,并且在具有这些类型的肿瘤的患者中,TAA表达不是普遍的。在这里,我们将端粒酶催化亚基(hTERT)表征为能够触发抗肿瘤细胞毒性T淋巴细胞(CTL)反应的广泛表达的TAA。超过85%的人类癌症表现出强大的端粒酶活性,但正常的成人组织,除少数例外,没有。在人类系统中,hTERT肽特异的CD8 + CTL并限制于MHC HLA-A2溶解的来自多种组织学的hTERT +肿瘤。这些发现确定了hTERT是抗癌免疫治疗策略的潜在重要且广泛适用的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号